Abstract
Biotherapeutics are large molecule drugs which are developed against targets that are not readily affected by small chemical compounds. This chapter covers mainly protein drugs, as well as the recombinant DNA technology used to produce these molecules in large quantities. Several sections are dedicated to the antibody drugs that are beginning to take a significant share of the pharmaceuticals market.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Notes
- 1.
It is possible to produce antibodies to carbohydrates and other molecules, but protein antigens make up by far the greatest number of targets for antibody drugs.
References
Ablynx Website (2010). http://www.ablynx.com/research/. Accessed 20 Nov 2010
Kim SJ et al (2005) Antibody engineering for the development of therapeutic antibodies. Mol Cells 20:17–29
McCafferty J (1990) Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348:552–554
Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663–76
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Zanders, E.D. (2011). Biotherapeutics. In: The Science and Business of Drug Discovery. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-9902-3_8
Download citation
DOI: https://doi.org/10.1007/978-1-4419-9902-3_8
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4419-9901-6
Online ISBN: 978-1-4419-9902-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)